- Issuer ticker
-
KLRA
- Reported as of
-
07 Sep 2026
- Net transaction value
-
$0
- SEC form
-
4
- Accepted by SEC
-
09 Sep 2026, 19:29:45 UTC
Filing notes and source
Key filing fact
Nur Nicholson filed Form 4 for Kailera Therapeutics, Inc. (KLRA) on 09 Sep 2026.
Key facts
- This page summarizes Nur Nicholson's Form 4 filing for Kailera Therapeutics, Inc. (KLRA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 09 Sep 2026, 19:29.
Change
- Previous filing in this sequence was filed on 09 Sep 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reporting Owners (1)
CIK 0001827317
Primary reporting owner
Nicholson Nur
- Relationship
-
Chief Technology Officer
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KLRA
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +220,000
- Change %
- Price
-
$0.000000*
- Shares after
- 220,000
- Date
- 07 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 220,000
- Exercise price
- $16.23
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Explanation of responses
1 footnote